Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
6.
An Med Interna ; 16(10): 498-503, 1999 Oct.
Article in Spanish | MEDLINE | ID: mdl-10603666

ABSTRACT

OBJECTIVE: To analyze the characteristics and control of hypertensive patients visited in a hospital hypertension clinic, dependent of the internal medicine department. METHODS: The study included 597 hypertensive patients, mean age 51.9 years (range 14-85), visited consecutively during the period 1989-1998. We applied the following initial protocol: Usual and orientated HBP anamnesis and physical examination, routine blood and urine test, standard electrocardiography and abdominal echocardiography. If necessary, we indicated other test or special explorations. After every visit, the data were stored into an electronic database, which we analyzed retrospectively to obtain the data of this study. RESULTS: Initial and final BP were: systolic BP 154 +/- 25 vs 141 +/- 21 mmHg, Dif. -12.9 (95% CI -14.8 a -11.0), and diastolic BP 96 +/- 12 vs 88 +/- 19 mmHg, Dif. -7.6 (95% CI -8.6 a -6.6). Four hundred and five patients (79.5%) presented I-II OMS stage and 121 (20.2%) III stage. One hundred and seventy-four cardiovascular events were registered. Hypercholesterolemia and obesity were present in 32% of the patients. Seventy-four (10.7%) had secondary HBP. ECA inhibitors were the antihypertensive drugs more used, either associated (58.9%) or as monotherapy (37%). Nine hundred patients (31.8%) presented optimal BP control (< 140/90 mmHg), and 27 (4.5%) refractory HBP. Weight and laboratory values (but uric acid) did not change significantly during the follow-up period. CONCLUSIONS: The patients showed a high prevalence of severe cardiovascular events, and associated risk factors. The 10% presented secondary HBP. About 31% of the patients reached optimal BP control.


Subject(s)
Antihypertensive Agents/therapeutic use , Hypertension/diagnosis , Hypertension/drug therapy , Adolescent , Adrenergic alpha-Antagonists/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Adult , Aged , Aged, 80 and over , Angiotensin II/antagonists & inhibitors , Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Calcium Channel Blockers/therapeutic use , Cardiovascular Diseases/complications , Data Interpretation, Statistical , Diabetes Complications , Diuretics/therapeutic use , Female , Follow-Up Studies , Humans , Hypercholesterolemia/complications , Hypertension/complications , Male , Middle Aged , Obesity/complications , Outpatients , Risk Factors , Time Factors
7.
An. med. interna (Madr., 1983) ; 16(10): 498-503, oct. 1999. tab
Article in Es | IBECS | ID: ibc-99

ABSTRACT

Objetivo: Analizar las características y el control de los pacientes hipertensos visitados en una consulta de hipertensión arterial (HTA), de nivel hospitalario, dependiente del servicio de medicina interna. Método: Se incluyeron 597 hipertensos, edad media 51,9 años (limites 14-85), visitados consecutivamente durante el período 1989-1998. Se aplicó el siguiente protocolo inicial de estudio: Anamnesis y exploración física general y orientada a HTA, analítica de sangre y orina de rutina, electrocardiograma y ecografía abdominal. Si se consideró necesario, se indicaron otras determinaciones o pruebas especiales. Después de cada visita, los datos se almacenaban en un archivo informático, de cuyo análisis retrospectivo se obtuvieron los datos presentados en este estudio. Resultados: La media de presión arterial (TA) al principio y final del seguimiento fue: TA sistólica 154 ± 25 vs 141 ± 21 mmHg, Dif. -12,9 (IC, 95%-14,8 a -11,0), y TA diastólica 96 ± 12 vs 88 ± 19 mmHg, Dif. -7,6 (IC, 95% -8,6 a -6,6). Cuatrocientos setenta y cinco (79,5%) presentaban estadio OMS I-II y 121 (20,2%) estadio III. Se registraron 174 complicaciones cardiovasculares graves. La hipercolesterolemia y la obesidad, estuvieron presentes en el 32 porciento de pacientes. Sesenta y cuatro (10,7%) presentaron HTA secundaria. Los fármacos antihipertensivos más utilizados fueron los inhibidores de la ECA, en asociación (58,9%) o en monoterapia (37%). Ciento noventa pacientes (31,8%) presentaron buen control tensional (<140/90 mmHg), y 27 (4,5%) HTA refractaria. El peso y los parámetros analíticos (excepto los uratos) no variaron significativamente durante el seguimiento. Conclusión: Los pacientes mostraron una alta prevalencia de complicaciones cardiovasculares graves y de factores de riesgo asociados. El 10% presentaron HTA secundaria. En torno al 31% de los pacientes alcanzó un control óptimo de la TA (AU)


Subject(s)
Adolescent , Adult , Aged , Female , Middle Aged , Aged, 80 and over , Humans , Adrenergic alpha-Antagonists/therapeutic use , Adrenergic beta-Antagonists/therapeutic use , Angiotensin II/antagonists & inhibitors , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents , Calcium Channels/therapeutic use , Cardiovascular Diseases/complications , Data Interpretation, Statistical , Diabetes Mellitus/complications , Diuretics/therapeutic use , Follow-Up Studies , Hypercholesterolemia/complications , Hypertension/complications , Obesity/complications , Receptors, Angiotensin/antagonists & inhibitors , Risk Factors , Time Factors , Outpatients , Antihypertensive Agents/therapeutic use , Hypertension/diagnosis , Hypertension/drug therapy
11.
An Esp Pediatr ; 33(1): 58-60, 1990 Jul.
Article in Spanish | MEDLINE | ID: mdl-2252289

ABSTRACT

Homozygous familiar hypercholesterolemia (FH) is a serious inherited disease caused by a genetic defect in the cell surface receptor that controls the degradation of low density lipoprotein (LDL). These patients often have myocardial infarction in their teens or early adulthood and are usually unresponsive to drugs. Recently it has been reported promising results using combined drugs regimens in patients with residual receptor activity. We report a new additional patient with receptor-defective homozygous FH treated with a combination of lovastatin and cholestyramine. The cholesterol levels were reduced in a 67% and there were adverse events related to treatment during a 7 month period of follow-up.


Subject(s)
Cholestyramine Resin/therapeutic use , Hyperlipoproteinemia Type II/genetics , Lovastatin/therapeutic use , Child, Preschool , Drug Therapy, Combination , Homozygote , Humans , Hyperlipoproteinemia Type II/drug therapy , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...